BioAge Labs is a biotechnology company harnessing the biology of human aging to develop new therapies for metabolic diseases. They utilize a proprietary multi-omics discovery platform to identify molecular mediators of aging and disease, with lead programs targeting cardiovascular risk and metabolic dysfunction.
Pioneering therapies that address the root cause of metabolic diseases by targeting the biology of human aging, using decades of multi-omics data to identify novel therapeutic pathways
AI Visibility Score
BioAge Labs has an AI visibility score of 59/100, rated as moderate. This score reflects how often and how prominently BioAge Labs appears in responses from AI assistants like ChatGPT, Claude, and Gemini.
AI Perception Summary
BioAge Labs is an undisputed leader in AI-driven multi-omics discovery, commanding a flawless 100% mention rate on ChatGPT and dominating Google AI Overviews for category leadership. Despite this technical authority, a massive intelligence gap exists as the brand remains largely invisible to Claude and Gemini users, missing critical representation in the metabolic and obesity research narratives.
Strengths
- Absolute dominance in AI and Multi-Omics Platform Discovery queries, particularly on ChatGPT where it holds the #1 position for human-first platform identification.
- High resonance with technical personas, specifically the Computational Biology Research Lead, achieving a 75% mention rate and an elite 2.7 average position.
- Strong trust signal integration, evidenced by holding the #1 spot in AI Overviews for queries regarding human-first data-backed biotechnology companies.
Visibility Gaps
- Significant underperformance on Claude and Gemini, where mention rates plummet to 25% and 31% respectively, leaving the brand out of critical longevity landscape conversations.
- Poor penetration in the 'Next-Gen Obesity and Cardiovascular Research' segment, failing to appear in several key clinical trial queries for NLRP3 inhibitors.
- Visibility with the Biotech Venture Partner persona is lagging at 38%, indicating that AI models do not yet strongly associate the brand with investment-grade longevity analysis.
Competitors in AI Recommendations
- Alphabet: 18 mentions
- Altos Labs: 17 mentions
- Unity Biotechnology: 14 mentions
- Insilico Medicine: 14 mentions
- Eli Lilly: 13 mentions
- Novartis: 11 mentions
- Calico Life Sciences: 10 mentions
- Elysium Health: 9 mentions
- Calico: 9 mentions
- Roche: 8 mentions
- Novo Nordisk: 8 mentions
- Calico Labs: 7 mentions
- Juvenescence: 6 mentions
- Cambrian Biopharma: 5 mentions
- AbbVie: 5 mentions
Categories: Biotechnology & Pharmaceuticals